A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency

Study protocol and review of the literature

Monica Mittal*, Michael Savvas, Roopen Arya, Carmel McEniery, Nitish Narvekar, Linda Cardozo, Nick Panay, Haitham Hamoda

*Corresponding author for this work

    Research output: Contribution to journalArticle

    5 Citations (Scopus)


    Premature ovarian insufficiency (POI) can have significant health implications for the affected patient population, but remains a largely under researched area. There is lack of evidence from randomised controlled trials to guide clinical practice, regarding the optimal hormone replacement therapy regimens, dose and route of administration. Furthermore, little research has addressed the effect of the various progestogens used on health parameters in women with POI. Here we describe an ongoing randomised clinical trial looking at the effects of micronized progesterone and medroxyprogesterone acetate, both used in combination with transdermal oestradiol on the cardiovascular system, lipid profile and coagulation cascade in women with POI as a step towards better understanding of the implications of hormone treatment in this cohort of women.

    Original languageEnglish
    Pages (from-to)127-132
    Number of pages6
    JournalMenopause international
    Issue number3
    Publication statusPublished - 2013



    • Estrogen
    • HRT
    • Menopause

    Cite this